The HBV DNA cutoff value for discriminating patients with HBeAgnegative chronic hepatitis B from inactive carriers

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Patients with HBeAg-negative chronic hepatitis B (CHB) has a significantly different prognosis than inactive carriers; there is however, no reliable strategy for accurately differentiating these two disease conditions. Objectives: To determine a strategy for discriminating patients with HBeAg-negative CHB from inactive carriers. Materials and Methods: Consecutive inactive carriers (i.e. HBeAg-negativity anti-HBe-positivity normal ALT levels, and HBV DNA < 2000 IU/mL) were enrolled. HBV reactivation was defined as the elevation of the HBV DNA level to ≥ 2000 IU/mL. Patients were classified into true inactive carriers when their HBV DNA levels remained at < 2000 IU/mL or false inactive carriers when their HBV DNA levels increased to ≥ 2000 IU/mL during the first year. Results: The Mean ± SD age of 208 inactive carriers (140 males) was 47.7 ± 12.6 years. The Mean ± SD serum ALT and HBV DNA levels were 22.8 ± 8.6 IU/L and 360 ± 482 IU/ mL, respectively. HBV reactivation developed in 41 (19.7%) patients during the first year. Baseline HBV DNA and ALT levels differed significantly between true inactive and false inactive carriers. The AUROCs of the baseline ALT and HBV DNA levels for predicting a false inactive carrier were 0.609 and 0.831, respectively. HBV reactivation developed more often in patients with a baseline HBV DNA level of ≥ 200 IU/mL than in those with a baseline HBV DNA level of < 200 IU/mL during a Mean ± SD follow-up of 622 ± 199 days. Conclusions: The HBV DNA level was useful for discriminating patients with HBeAg-negative CHB from true inactive carriers. The follow-up strategies applied to inactive carriers need to vary with their HBV DNA levels.

Original languageEnglish
Pages (from-to)351-357
Number of pages7
JournalHepatitis Monthly
Volume11
Issue number5
Publication statusPublished - 2011 May 1

Fingerprint

Chronic Hepatitis B
DNA
Hepatitis B e Antigens

Keywords

  • Hepatitis B virus
  • Inactive carrier
  • Reactivation

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

@article{2bf6e20d2a714b5091309557215545be,
title = "The HBV DNA cutoff value for discriminating patients with HBeAgnegative chronic hepatitis B from inactive carriers",
abstract = "Background: Patients with HBeAg-negative chronic hepatitis B (CHB) has a significantly different prognosis than inactive carriers; there is however, no reliable strategy for accurately differentiating these two disease conditions. Objectives: To determine a strategy for discriminating patients with HBeAg-negative CHB from inactive carriers. Materials and Methods: Consecutive inactive carriers (i.e. HBeAg-negativity anti-HBe-positivity normal ALT levels, and HBV DNA < 2000 IU/mL) were enrolled. HBV reactivation was defined as the elevation of the HBV DNA level to ≥ 2000 IU/mL. Patients were classified into true inactive carriers when their HBV DNA levels remained at < 2000 IU/mL or false inactive carriers when their HBV DNA levels increased to ≥ 2000 IU/mL during the first year. Results: The Mean ± SD age of 208 inactive carriers (140 males) was 47.7 ± 12.6 years. The Mean ± SD serum ALT and HBV DNA levels were 22.8 ± 8.6 IU/L and 360 ± 482 IU/ mL, respectively. HBV reactivation developed in 41 (19.7{\%}) patients during the first year. Baseline HBV DNA and ALT levels differed significantly between true inactive and false inactive carriers. The AUROCs of the baseline ALT and HBV DNA levels for predicting a false inactive carrier were 0.609 and 0.831, respectively. HBV reactivation developed more often in patients with a baseline HBV DNA level of ≥ 200 IU/mL than in those with a baseline HBV DNA level of < 200 IU/mL during a Mean ± SD follow-up of 622 ± 199 days. Conclusions: The HBV DNA level was useful for discriminating patients with HBeAg-negative CHB from true inactive carriers. The follow-up strategies applied to inactive carriers need to vary with their HBV DNA levels.",
keywords = "Hepatitis B virus, Inactive carrier, Reactivation",
author = "Eun-Sun Kim and Seo, {Yeon Seok} and Bora Keum and Kim, {Ji Hoon} and Hyonggin An and Yim, {Hyung Joon} and Kim, {Yong Sik} and Jeen, {Yoon Tae} and Lee, {Hong Sik} and Hoon-Jai Chun and Soon-Ho Um and Kim, {Chang Duck} and Ryu, {Ho Sang}",
year = "2011",
month = "5",
day = "1",
language = "English",
volume = "11",
pages = "351--357",
journal = "Hepatitis Monthly",
issn = "1735-143X",
publisher = "Kowsar Publishing Company",
number = "5",

}

TY - JOUR

T1 - The HBV DNA cutoff value for discriminating patients with HBeAgnegative chronic hepatitis B from inactive carriers

AU - Kim, Eun-Sun

AU - Seo, Yeon Seok

AU - Keum, Bora

AU - Kim, Ji Hoon

AU - An, Hyonggin

AU - Yim, Hyung Joon

AU - Kim, Yong Sik

AU - Jeen, Yoon Tae

AU - Lee, Hong Sik

AU - Chun, Hoon-Jai

AU - Um, Soon-Ho

AU - Kim, Chang Duck

AU - Ryu, Ho Sang

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Background: Patients with HBeAg-negative chronic hepatitis B (CHB) has a significantly different prognosis than inactive carriers; there is however, no reliable strategy for accurately differentiating these two disease conditions. Objectives: To determine a strategy for discriminating patients with HBeAg-negative CHB from inactive carriers. Materials and Methods: Consecutive inactive carriers (i.e. HBeAg-negativity anti-HBe-positivity normal ALT levels, and HBV DNA < 2000 IU/mL) were enrolled. HBV reactivation was defined as the elevation of the HBV DNA level to ≥ 2000 IU/mL. Patients were classified into true inactive carriers when their HBV DNA levels remained at < 2000 IU/mL or false inactive carriers when their HBV DNA levels increased to ≥ 2000 IU/mL during the first year. Results: The Mean ± SD age of 208 inactive carriers (140 males) was 47.7 ± 12.6 years. The Mean ± SD serum ALT and HBV DNA levels were 22.8 ± 8.6 IU/L and 360 ± 482 IU/ mL, respectively. HBV reactivation developed in 41 (19.7%) patients during the first year. Baseline HBV DNA and ALT levels differed significantly between true inactive and false inactive carriers. The AUROCs of the baseline ALT and HBV DNA levels for predicting a false inactive carrier were 0.609 and 0.831, respectively. HBV reactivation developed more often in patients with a baseline HBV DNA level of ≥ 200 IU/mL than in those with a baseline HBV DNA level of < 200 IU/mL during a Mean ± SD follow-up of 622 ± 199 days. Conclusions: The HBV DNA level was useful for discriminating patients with HBeAg-negative CHB from true inactive carriers. The follow-up strategies applied to inactive carriers need to vary with their HBV DNA levels.

AB - Background: Patients with HBeAg-negative chronic hepatitis B (CHB) has a significantly different prognosis than inactive carriers; there is however, no reliable strategy for accurately differentiating these two disease conditions. Objectives: To determine a strategy for discriminating patients with HBeAg-negative CHB from inactive carriers. Materials and Methods: Consecutive inactive carriers (i.e. HBeAg-negativity anti-HBe-positivity normal ALT levels, and HBV DNA < 2000 IU/mL) were enrolled. HBV reactivation was defined as the elevation of the HBV DNA level to ≥ 2000 IU/mL. Patients were classified into true inactive carriers when their HBV DNA levels remained at < 2000 IU/mL or false inactive carriers when their HBV DNA levels increased to ≥ 2000 IU/mL during the first year. Results: The Mean ± SD age of 208 inactive carriers (140 males) was 47.7 ± 12.6 years. The Mean ± SD serum ALT and HBV DNA levels were 22.8 ± 8.6 IU/L and 360 ± 482 IU/ mL, respectively. HBV reactivation developed in 41 (19.7%) patients during the first year. Baseline HBV DNA and ALT levels differed significantly between true inactive and false inactive carriers. The AUROCs of the baseline ALT and HBV DNA levels for predicting a false inactive carrier were 0.609 and 0.831, respectively. HBV reactivation developed more often in patients with a baseline HBV DNA level of ≥ 200 IU/mL than in those with a baseline HBV DNA level of < 200 IU/mL during a Mean ± SD follow-up of 622 ± 199 days. Conclusions: The HBV DNA level was useful for discriminating patients with HBeAg-negative CHB from true inactive carriers. The follow-up strategies applied to inactive carriers need to vary with their HBV DNA levels.

KW - Hepatitis B virus

KW - Inactive carrier

KW - Reactivation

UR - http://www.scopus.com/inward/record.url?scp=79957646243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957646243&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 351

EP - 357

JO - Hepatitis Monthly

JF - Hepatitis Monthly

SN - 1735-143X

IS - 5

ER -